Pulse Biosciences Inc.
PLSE | NASDAQ
$52.24
-$3.24 (-5.84%)
At close: Oct 30, 2026, 4:00 PM ET
$51.00
-$1.24 (-2.37%)
Pre-market:
Nov 2, 2026, 7:12 AM ET
Company Profile
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Key Executives
| Name | Position |
|---|---|
| Paul Arthur LaViolette | President, Chief Executive Officer & Co-Chairman of the Board |
| Darrin R. Uecker | Chief Technology Officer & Director |
| Jon Skinner | Chief Financial Officer |
| Liane Teplitsky | Chief Operating Officer |
| David Danitz | Senior Vice President of Engineering |
| Gansevoort Dunnington | Chief Medical Officer |
| Kenneth Stratton | General Counsel & Corporate Secretary |
| Niv Ad | Chief Science Officer of Cardiac Surgery |
| Patty Perla | Vice President of Human Resources |
| Steven T. Weber | Vice President of Accounting, Principal Accounting Officer & Global Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 15, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 424B5 | Filing |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 3 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 3 | Filing |
| Aug 06, 2026 | 8-K | Current Report |
Pulse Biosciences Inc.
| Country | United States |
| IPO Date | May 18, 2016 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Paul Arthur LaViolette |
Contact Details
601 Brickell Key Drive Miami,
Florida 33131 United States
Stock Details
| Ticker Symbol | PLSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625101 |
| CUSIP Number | 74587B101 |
| ISIN Number | US74587B1017 |
| SIC Code | 3841 |
Recent News
- 3 days ago / businesswire.comPulse Biosciences to Present at Stifel 2026 Healthcare Conference
- 11 days ago / businesswire.comPulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
- 19 days ago / businesswire.comPulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
- 25 days ago / businesswire.comPulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
- 2 months ago / fool.comWhy Pulse Biosciences Stock Popped Today
- 3 months ago / seekingalpha.comPulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
- 3 months ago / marketbeat.comPulse Biosciences Q2 Earnings Call Highlights
- 3 months ago / zacks.comPulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
- 3 months ago / businesswire.comPulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
- 3 months ago / businesswire.comPulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
Add to Watchlist
Select watchlists to add or remove PLSE